DNA repair activity of 8-oxoguanine DNA glycosylase 1 (OGG1) in human lymphocytes is not dependent on genetic polymorphism Ser326/Cys326

2001 ◽  
Vol 486 (3) ◽  
pp. 207-216 ◽  
Author(s):  
Kai Janssen ◽  
Kirsten Schlink ◽  
Walter Götte ◽  
Birgit Hippler ◽  
Bernd Kaina ◽  
...  
Author(s):  
Philip A.J. Crosbie ◽  
Amanda J. Watson ◽  
Raymond Agius ◽  
Philip V. Barber ◽  
Geoffrey P. Margison ◽  
...  

2009 ◽  
Vol 83 (8) ◽  
pp. 777-784
Author(s):  
P. Finkenwirth ◽  
U. Spelmeyer ◽  
G. Hommel ◽  
D.-M. Rose ◽  
D. Jung ◽  
...  

2014 ◽  
Vol 290 (8) ◽  
pp. 4966-4980 ◽  
Author(s):  
Sanjay Adhikari ◽  
Mahandranauth A. Chetram ◽  
Jordan Woodrick ◽  
Partha S. Mitra ◽  
Praveen V. Manthena ◽  
...  

2020 ◽  
Vol 401 (12) ◽  
pp. 1487-1493
Author(s):  
Stephan Kiontke ◽  
Tanja Göbel ◽  
Annika Brych ◽  
Alfred Batschauer

AbstractDrosophila, Arabidopsis, Synechocystis, human (DASH)-type cryptochromes (cry-DASHs) form one subclade of the cryptochrome/photolyase family (CPF). CPF members are flavoproteins that act as DNA-repair enzymes (DNA-photolyases), or as ultraviolet(UV)-A/blue light photoreceptors (cryptochromes). In mammals, cryptochromes are essential components of the circadian clock feed-back loop. Cry-DASHs are present in almost all major taxa and were initially considered as photoreceptors. Later studies demonstrated DNA-repair activity that was, however, restricted to UV-lesions in single-stranded DNA. Very recent studies, particularly on microbial organisms, substantiated photoreceptor functions of cry-DASHs suggesting that they could be transitions between photolyases and cryptochromes.


Oncotarget ◽  
2017 ◽  
Vol 8 (28) ◽  
pp. 45072-45087 ◽  
Author(s):  
Li-Fang Lin ◽  
Ming-Hsi Wu ◽  
Vijaya Kumar Pidugu ◽  
I-Ching Ho ◽  
Tsann-Long Su ◽  
...  

2002 ◽  
Vol 49 (1) ◽  
pp. 145-155 ◽  
Author(s):  
Janusz Błasiak ◽  
Ewa Gloc ◽  
Mariusz Warszawski

Idarubicin is an anthracycline antibiotic used in cancer therapy. Mitoxantrone is an anthracycline analog with presumed better antineoplastic activity and lesser toxicity. Using the alkaline comet assaywe showed that the drugs at 0.01-10 microM induced DNA damage in normal human lymphocytes. The effect induced by idarubicin was more pronounced than by mitoxantrone (P < 0.001). The cells treated with mitoxantrone at 1 microM were able to repair damage to their DNA within a 30-min incubation, whereas the lymphocytes exposed to idarubicin needed 180 min. Since anthracyclines are known to produce free radicals, we checked whether reactive oxygen species might be involved in the observed DNA damage. Catalase, an enzyme inactivating hydrogen peroxide, decreased the extent of DNA damage induced by idarubicin, but did not affect the extent evoked by mitoxantrone. Lymphocytes exposed to the drugs and treated with endonuclease III or formamidopyrimidine-DNA glycosylase (Fpg), enzymes recognizing and nicking oxidized bases, displayed a higher level of DNA damage than the untreated ones. 3-Methyladenine-DNA glycosylase II (AlkA), an enzyme recognizing and nicking mainly methylated bases in DNA, increased the extent of DNA damage caused by idarubicin, but not that induced by mitoxantrone. Our results indicate that the induction of secondary malignancies should be taken into account as side effects of the two drugs. Direct strand breaks, oxidation and methylation of the DNA bases can underlie the DNA-damaging effect of idarubicin, whereas mitoxantrone can induce strand breaks and modification of the bases, including oxidation. The observed in normal lymphocytes much lesser genotoxicity of mitoxantrone compared to idarubicin should be taken into account in planning chemotherapeutic strategies.


Sign in / Sign up

Export Citation Format

Share Document